99 results about "Dihydrotestosterone" patented technology

A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

A formulation for drug delivery, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of a lipophilic therapeutic agent by formulation with sterols and/or sterol esters, resulting in higher bioavailability of a therapeutic agent administered to a subject in need of such therapeutic agent. The formulation contains a therapeutic agent and a sterol or sterol ester, and can, optionally, further contain a solubilizer and/or an enhancing agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

The present invention describes a composition that contains a plant sterol or plant stanol or their fatty acid esters and an emulsifier for treating conditions that are related to elevated dihydrotestosterone. The compositions can be prepared in a dry form for use as a food ingredient, tablet or capsule. Alternatively, the compositions can be dissolved in oil.

The composition of the invention relates generally to a nutritional supplement, which is capable of ameliorating the biologically detrimental effects of dihydrotestosterone (DHT). The present composition comprises a combination of natural plant-derived extracts, and minerals including Saw palmetto berry extract; pumpkin seed (Curcubito pepo) extract; beta-sitosterol; quercetin; Polygonum multiflorum root extract; a lycopene, for example from tomato extract; isoflavones, for example from Pueraria lobata root extract, and soybeans; zinc; selenium or any combination thereof. The ingredients are combined into any suitable form to be administered, and consumed by an individual for the prevention or treatment of hair loss, or prostatic hyperplasia or both.

The invention relates to a method for determining dihydrotestosterone in a medicine through a derivatization HPLC method. The method comprises the steps that (1) a benzoyl halide compound is used as aderivatization reagent to carry out derivatization reaction on dihydrotestosterone in a medicine to be tested to acquire a sample containing a dihydrotestosterone derivatization product; and (2) a test solution is prepared by using the sample containing the dihydrotestosterone derivatization product, and the test solution is detected by high performance liquid chromatography, wherein the detectorof the high performance liquid chromatography is an ultraviolet detector. According to the invention, the method for determining dihydrotestosterone through derivatization HPLC-UVD is simple and versatile, and can be used for the determination of the medicine content in dihydrotestosterone preparations; and a methodology validation result shows that the method has the advantages of specificity, good sensitivity and high accuracy.

The invention discloses a recipe for treating androgenetic alopecia, a liquid shampoo and an application method for the recipe. The recipe comprises, by weight, 41 to 50% of potassium azeloyl diglycinate, 6 to 12% of water-soluble hesperidin, 1.6 to 9% of vitamin C and 1.2 to 6.3% of vitamin B. The application method for the recipe comprises the following steps: mixing the recipe with deionized water according to a mass ratio of 0.8-1.2: 9; heating a mixture obtained in the previous step to 40 DEG C and carrying out isothermal stirring for 10 min; and carrying out natural cooling to room temperature under stirring. When used as an external 5a-reductase inhibitor, the recipe provided by the invention can reduce dihydrotestosterone in scalps and hair follicles and improve and strengthen 5a-reductase inhibitory effect; through cooperation with vitamin B, absorption and action of vitamin B are improved, and potassium azeloyl diglycinate has improved 5a-reductase inhibitory effect; and cooperation between methyl hesperidin and vitamin C can improve the blood flow volume of capillary vessels in scalps, is beneficial for hair growth and exerts same effect as minoxidil.

The invention discloses a composition for inhibiting the activity of 5 alpha-reductase. The composition comprises lycopene, curcumin and aromatic turmerone. Researches find that compared with a singleplant extract and a model control group, the composition disclosed by the invention can obviously inhibit the activity of the 5alpha-reductase, reduces the dihydrotestosterone content in animal tissues and serum, obviously induces the activity reduction of benign prostatic hyperplasia cells and human prostatic hyperplasia epithelial cells, obviously induces the proliferation of human sebaceous gland cells, obviously promotes the proliferation of human papilla dermal cells, and has an obvious synergistic interaction effect on the prevention and treatment of prostate diseases, androgenic alopecia or acne and other androgenic diseases. The plant extract composition provided by the invention is efficient and free of toxic and side effects, and has important application value in prevention andtreatment of androgen diseases..

An improved hair color formulation treats hair to provide volume, viscosity, color and hair follicle stimulation. The color formulation is appointed to be used in hair products, and comprises a natural color agent and at least one agent providing anti-dihydrotestosterone (DHT) effects. Hair products include styling products, cleansing products, concealment products, and dying products. In one embodiment, the formulation comprises an aqueous emulsion, at least one hydrocarbon, at least one thickening agent, at least one humectant, at least one emollient, at least one fatty acid ester, and at least one agent providing anti-dihydrotestosterone (DHT) effects, such as caffeine, and at least one color agent. Preservatives, fibers and further treatments for male/female pattern baldness may also be added to the composition. Natural colorants are added to the hair color formulation to provide temporary coloring in addition to enhanced volume, viscosity and hair follicle stimulation.

A SEDDS or SMEDDS or SNEDDS formulation for drug delivery of a lipophilic therapeutic agent, providing enhanced modulation of solubility, stability, absorption, metabolism, and/or pharmacokinetic profile of the therapeutic agent by formulation with a lipophilic surfactant, a hydrophilic surfactant, one or more solubilizers and, optionally, digestible oils, resulting in higher bioavailability of the therapeutic agent administered to a subject in need of such therapeutic agent. Also described are pharmaceutical compositions containing the formulations and methods of making and methods of using the formulations and pharmaceutical compositions. Formulations of the disclosure can be constituted to minimize the synthesis of dihydrotestosterone when the therapeutic agent includes testosterone or testosterone esters.

The invention discloses a steroid hormone detection method that comprises the following steps: adding an internal standard substance into a sample to be detected; carrying out a derivatization reaction; detecting an analyte by using chromatography tandem mass spectrometry; the analyte comprises a first steroid hormone and a second steroid hormone at the same time; the first steroid hormone is selected from at least one of the following steroid hormones: estradiol and estriol; and the second steroid hormone is selected from at least one of the following steroid hormones: dehydroepiandrosterone,dehydroepiandrosterone sulfate, testosterone, dihydrotestosterone, androstenedione, cortisol, cortisone, 11-deoxycortisol, 17alpha-hydroxyprogesterone, 17alpha-hydroxypregnenolone, aldosterone, cortisol, deoxycortisol, progesterone and pregnenolone. The detecting method has the advantages of few operation steps and short detection time, and can specifically, sensitively, accurately and quantitatively analyze the analyte substance.

The invention dislcoses application of crocetin in preparation of a drug or a health care product for preventing and treating polycystic ovarian syndrome. On the basis of the existing effects of the crocetin, a foetal period dihydrotestosterone-induced polycystic ovarian syndrome mouse model is adopted to deeply research therapeutic action of the crocetin. Results show that the crocetin can remarkably relieve estrous cycle dysrhythmia of a polycystic ovarian syndrome model mouse, reduce ovary weight and an atresia ovary amount, increasing amounts of corpora lutea big antral follicles and follicles before ovulation, and remarkably improve levels of estradiol, luteinizing hormone, follicle-stimulating hormone, progesterone and testosterone of the polycystic ovarian syndrome model mouse, andhas a good effect of treating the polycystic ovarian syndrome. Moreover, in an experiment process, obviously untoward effects do not appear, and the safety is high.